{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T16:42:29Z","timestamp":1791996149296,"version":"4.4.0"},"reference-count":120,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,3,28]],"date-time":"2023-03-28T00:00:00Z","timestamp":1679961600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"<jats:p>Heart failure is a serious threat to human health, with morbidity and mortality rates increasing despite the existence of multiple treatment options. Therefore, it is necessary to identify new therapeutic targets for this disease. Sacubitril\/valsartan is a supramolecular sodium salt complex of the enkephalinase inhibitor prodrug sacubitril and the angiotensin receptor blocker valsartan. Its combined action increases endogenous natriuretic peptides while inhibiting the renin-angiotensin-aldosterone system and exerting cardioprotective effects. Clinical evidence suggests that sacubitril\/valsartan is superior to conventional renin-angiotensin-aldosterone inhibitor therapy for patients with reduced ejection fraction heart failure who can tolerate angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers. The therapy reduces the risk of heart failure hospitalization, cardiovascular mortality, and all-cause mortality and has a better safety and tolerability record. This review describes the potential pathophysiological mechanisms of cardiomyocyte injury amelioration by sacubitril\/valsartan. We explore the protective effects of sacubitril\/valsartan and outline the therapeutic value in patients with heart failure by summarizing the results of recent large clinical trials. Furthermore, a preliminary outlook shows that sacubitril\/valsartan may be effective at treating other diseases, and provides some exploratory observations that lay the foundation for future studies on this drug.<\/jats:p>","DOI":"10.3389\/fcvm.2023.1102521","type":"journal-article","created":{"date-parts":[[2023,3,28]],"date-time":"2023-03-28T05:00:40Z","timestamp":1679979640000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":22,"title":["The history and mystery of sacubitril\/valsartan: From clinical trial to the real world"],"prefix":"10.3389","volume":"10","author":[{"given":"Mingsong","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yifei","family":"Zou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yangxue","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"He","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,3,28]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1093\/eurheartj\/ehw128","article-title":"2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European society of cardiology (ESC) developed with the special contribution of the heart failure association (HFA) of the ESC","volume":"37","author":"Ponikowski","year":"2016","journal-title":"Eur Heart J"},{"key":"B2","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1093\/eurheartj\/12.suppl_d.190","article-title":"Hormones in heart failure\u2013regulation and counterregulation","volume":"12","author":"Riegger","year":"1991","journal-title":"Eur Heart J"},{"key":"B3","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1002\/cphy.c140055","article-title":"Pathophysiology of heart failure","volume":"6","author":"Tanai","year":"2015","journal-title":"Compr Physiol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/j.ijcard.2018.04.045","article-title":"Natriuretic peptides in heart failure: current achievements and future perspectives","volume":"281","author":"Volpe","year":"2019","journal-title":"Int J Cardiol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1097\/00004872-199203000-00011","article-title":"Candoxatril, an orally active neutral endopeptidase inhibitor, raises plasma atrial natriuretic factor and is natriuretic in essential hypertension","volume":"10","author":"O'Connell","year":"1992","journal-title":"J Hypertens"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1161\/circulationaha.115.018622","article-title":"Combined angiotensin receptor antagonism and neprilysin inhibition","volume":"133","author":"Hubers","year":"2016","journal-title":"Circulation"},{"key":"B7","doi-asserted-by":"publisher","first-page":"650124","DOI":"10.3389\/fphys.2021.650124","article-title":"Toward a new paradigm for targeted natriuretic peptide enhancement in heart failure","volume":"12","author":"Gidlof","year":"2021","journal-title":"Front Physiol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"e895","DOI":"10.1161\/CIR.0000000000001063","article-title":"2022 AHA\/ACC\/HFSA guideline for the management of heart failure: a report of the American college of cardiology\/American heart association joint committee on clinical practice guidelines","volume":"145","author":"Heidenreich","year":"2022","journal-title":"Circulation"},{"key":"B9","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1177\/0091270009343932","article-title":"Pharmacokinetics and pharmacodynamics of LCZ696, a novel dual-acting angiotensin receptor-neprilysin inhibitor (ARNi)","volume":"50","author":"Gu","year":"2010","journal-title":"J Clin Pharmacol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1007\/s40262-017-0543-3","article-title":"Clinical pharmacokinetics of sacubitril\/valsartan (LCZ696): a novel angiotensin receptor-neprilysin inhibitor","volume":"56","author":"Ayalasomayajula","year":"2017","journal-title":"Clin Pharmacokinet"},{"key":"B11","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1373\/clinchem.2016.262907","article-title":"Biochemistry, therapeutics, and biomarker implications of neprilysin in cardiorenal disease","volume":"63","author":"Chen","year":"2017","journal-title":"Clin Chem"},{"key":"B12","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1007\/s40265-016-0544-9","article-title":"Sacubitril\/valsartan: a review in chronic heart failure with reduced ejection fraction","volume":"76","author":"McCormack","year":"2016","journal-title":"Drugs"},{"key":"B13","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1038\/nrcardio.2016.200","article-title":"Long-term neprilysin inhibition\u2014implications for ARNIs","volume":"14","author":"Campbell","year":"2017","journal-title":"Nat Rev Cardiol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"125","DOI":"10.2174\/1389450120666190821152000","article-title":"Angiotensin type 1 receptor blockers in heart failure","volume":"21","author":"Singh","year":"2020","journal-title":"Curr Drug Targets"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1007\/s10741-021-10137-2","article-title":"Current and emerging drug targets in heart failure treatment","volume":"27","author":"Ghionzoli","year":"2021","journal-title":"Heart Fail Rev"},{"key":"B16","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1080\/10641963.2018.1441862","article-title":"Sacubitril and valsartan protect from experimental myocardial infarction by ameliorating oxidative damage in wistar rats","volume":"41","author":"Imran","year":"2019","journal-title":"Clin Exp Hypertens"},{"key":"B17","doi-asserted-by":"publisher","first-page":"108954","DOI":"10.1016\/j.biopha.2019.108954","article-title":"The therapeutic impact of entresto on protecting against cardiorenal syndrome-associated renal damage in rats on high protein diet","volume":"116","author":"Yang","year":"2019","journal-title":"Biomed Pharmacother"},{"key":"B18","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/j.cardfail.2017.12.010","article-title":"LCZ696 (sacubitril\/valsartan), an angiotensin-receptor neprilysin inhibitor, attenuates cardiac hypertrophy, fibrosis, and vasculopathy in a rat model of chronic kidney disease","volume":"24","author":"Suematsu","year":"2018","journal-title":"J Card Fail"},{"key":"B19","doi-asserted-by":"publisher","first-page":"6509","DOI":"10.1038\/s41598-019-42994-1","article-title":"Neprilysin inhibitor-angiotensin II receptor blocker combination therapy (sacubitril\/valsartan) suppresses atherosclerotic plaque formation and inhibits inflammation in apolipoprotein E- deficient mice","volume":"9","author":"Zhang","year":"2019","journal-title":"Sci Rep"},{"key":"B20","doi-asserted-by":"publisher","first-page":"9582","DOI":"10.18632\/aging.202692","article-title":"LCZ696 Ameliorates lipopolysaccharide-induced endothelial injury","volume":"13","author":"Gao","year":"2021","journal-title":"Aging (Albany NY)"},{"key":"B21","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1152\/japplphysiol.00454.2020","article-title":"Sacubitril-valsartan improves conduit vessel function and functional capacity and reduces inflammation in heart failure with reduced ejection fraction","volume":"130","author":"Bunsawat","year":"2021","journal-title":"J Appl Physiol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"676","DOI":"10.3892\/mmr.2021.12315","article-title":"Sacubitril\/valsartan (LCZ696) reduces myocardial injury following myocardial infarction by inhibiting NLRP3induced pyroptosis via the TAK1\/JNK signaling pathway","volume":"24","author":"Shen","year":"2021","journal-title":"Mol Med Rep"},{"key":"B23","doi-asserted-by":"publisher","first-page":"654051","DOI":"10.3389\/fcell.2021.654051","article-title":"LCZ696 Attenuated doxorubicin-induced chronic cardiomyopathy through the TLR2-MyD88 Complex formation","volume":"9","author":"Ye","year":"2021","journal-title":"Front Cell Dev Biol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"402","DOI":"10.3892\/mmr.2021.12041","article-title":"Sacubitril\/valsartan inhibits oxLDLinduced MALAT1 expression, inflammation and apoptosis by suppressing the TLR4\/NFkappaB signaling pathway in HUVECs","volume":"23","author":"Bai","year":"2021","journal-title":"Mol Med Rep"},{"key":"B25","doi-asserted-by":"publisher","first-page":"112244","DOI":"10.1016\/j.biopha.2021.112244","article-title":"Entresto protected the cardiomyocytes and preserved heart function in cardiorenal syndrome rat fed with high-protein diet through regulating the oxidative stress and Mfn2-mediated mitochondrial functional integrity","volume":"144","author":"Yeh","year":"2021","journal-title":"Biomed Pharmacother"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.3390\/ijms23031288","article-title":"LCZ696 Protects against diabetic cardiomyopathy-induced myocardial inflammation, ER stress, and apoptosis through inhibiting AGEs\/NF-kappaB and PERK\/CHOP signaling pathways","volume":"23","author":"Belali","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1007\/s00204-022-03241-1","article-title":"Sacubitril\/valsartan reduces endoplasmic reticulum stress in a rat model of doxorubicin-induced cardiotoxicity","volume":"96","author":"Kim","year":"2022","journal-title":"Arch Toxicol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.yjmcc.2017.06.003","article-title":"LCZ696 Improves cardiac function via alleviating Drp1-mediated mitochondrial dysfunction in mice with doxorubicin-induced dilated cardiomyopathy","volume":"108","author":"Xia","year":"2017","journal-title":"J Mol Cell Cardiol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/j.ijcard.2018.01.077","article-title":"Angiotensin receptor neprilysin inhibition provides superior cardioprotection compared to angiotensin converting enzyme inhibition after experimental myocardial infarction","volume":"258","author":"Kompa","year":"2018","journal-title":"Int J Cardiol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1002\/ehf2.13177","article-title":"Sacubitril\/valsartan ameliorates cardiac hypertrophy and preserves diastolic function in cardiac pressure overload","volume":"8","author":"Norden","year":"2021","journal-title":"ESC Heart Fail"},{"key":"B31","doi-asserted-by":"publisher","first-page":"9815039","DOI":"10.1155\/2020\/9815039","article-title":"LCZ696 Ameliorates oxidative stress and pressure overload-induced pathological cardiac remodeling by regulating the Sirt3\/MnSOD pathway","volume":"2020","author":"Peng","year":"2020","journal-title":"Oxid Med Cell Longev"},{"key":"B32","doi-asserted-by":"publisher","first-page":"696472","DOI":"10.3389\/fphar.2021.696472","article-title":"Protective effects of sacubitril\/valsartan on cardiac fibrosis and function in rats with experimental myocardial infarction involves inhibition of collagen synthesis by myocardial fibroblasts through downregulating TGF-beta1\/smads pathway","volume":"12","author":"Wu","year":"2021","journal-title":"Front Pharmacol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"e015640","DOI":"10.1161\/JAHA.119.015640","article-title":"Sacubitril\/valsartan improves cardiac function and decreases myocardial fibrosis via downregulation of exosomal miR-181a in a rodent chronic myocardial infarction model","volume":"9","author":"Vaskova","year":"2020","journal-title":"J Am Heart Assoc"},{"key":"B34","doi-asserted-by":"publisher","first-page":"724147","DOI":"10.3389\/fphar.2021.724147","article-title":"Lcz696 alleviates myocardial fibrosis after myocardial infarction through the sFRP-1\/wnt\/beta-catenin signaling pathway","volume":"12","author":"Liu","year":"2021","journal-title":"Front Pharmacol"},{"key":"B35","doi-asserted-by":"publisher","first-page":"e005565","DOI":"10.1161\/CIRCHEARTFAILURE.118.005565","article-title":"Sacubitril\/valsartan decreases cardiac fibrosis in left ventricle pressure overload by restoring PKG signaling in cardiac fibroblasts","volume":"12","author":"Burke","year":"2019","journal-title":"Circ Heart Fail"},{"key":"B36","doi-asserted-by":"publisher","first-page":"760035","DOI":"10.3389\/fcell.2021.760035","article-title":"Sacubitril ameliorates cardiac fibrosis through inhibiting TRPM7 channel","volume":"9","author":"Jia","year":"2021","journal-title":"Front Cell Dev Biol"},{"key":"B37","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1016\/S0140-6736(12)61227-6","article-title":"Prospective comparison of AwARBoMOhfwpefI. The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial","volume":"380","author":"Solomon","year":"2012","journal-title":"Lancet"},{"key":"B38","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1161\/CIRCHEARTFAILURE.114.001427","article-title":"Elevation in high-sensitivity troponin T in heart failure and preserved ejection fraction and influence of treatment with the angiotensin receptor neprilysin inhibitor LCZ696","volume":"7","author":"Jhund","year":"2014","journal-title":"Circ Heart Fail"},{"key":"B39","doi-asserted-by":"publisher","first-page":"e005133","DOI":"10.1161\/CIRCHEARTFAILURE.118.005133","article-title":"IGFBP7 (insulin-like growth factor-binding protein-7) and neprilysin inhibition in patients with heart failure","volume":"11","author":"Januzzi","year":"2018","journal-title":"Circ Heart Fail"},{"key":"B40","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin-neprilysin inhibition versus enalapril in heart failure","volume":"371","author":"McMurray","year":"2014","journal-title":"N Engl J Med"},{"key":"B41","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1161\/CIRCULATIONAHA.114.013748","article-title":"Angiotensin receptor neprilysin inhibition compared with enalapril on the risk of clinical progression in surviving patients with heart failure","volume":"131","author":"Packer","year":"2015","journal-title":"Circulation"},{"key":"B42","doi-asserted-by":"publisher","first-page":"e002744","DOI":"10.1161\/CIRCHEARTFAILURE.115.002744","article-title":"Influence of ejection fraction on outcomes and efficacy of sacubitril\/valsartan (LCZ696) in heart failure with reduced ejection fraction: the prospective comparison of ARNI with ACEI to determine impact on global mortality and morbidity in heart failure (PARADIGM-HF) trial","volume":"9","author":"Solomon","year":"2016","journal-title":"Circ Heart Fail"},{"key":"B43","doi-asserted-by":"publisher","first-page":"1990","DOI":"10.1093\/eurheartj\/ehv186","article-title":"Effect of the angiotensin-receptor-neprilysin inhibitor LCZ696 compared with enalapril on mode of death in heart failure patients","volume":"36","author":"Desai","year":"2015","journal-title":"Eur Heart J"},{"key":"B44","doi-asserted-by":"publisher","first-page":"2576","DOI":"10.1093\/eurheartj\/ehv330","article-title":"Efficacy and safety of LCZ696 (sacubitril-valsartan) according to age: insights from PARADIGM-HF","volume":"36","author":"Jhund","year":"2015","journal-title":"Eur Heart J"},{"key":"B45","doi-asserted-by":"publisher","first-page":"003430","DOI":"10.1161\/CIRCHEARTFAILURE.116.003430","article-title":"Health-Related quality of life outcomes in PARADIGM-HF","volume":"10","author":"Lewis","year":"2017","journal-title":"Circ Heart Fail"},{"key":"B46","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1001\/jamacardio.2018.0398","article-title":"Effects of sacubitril\/valsartan on physical and social activity limitations in patients with heart failure: a secondary analysis of the PARADIGM-HF trial","volume":"3","author":"Chandra","year":"2018","journal-title":"JAMA Cardiol"},{"key":"B47","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1001\/jamacardio.2016.4733","article-title":"Reduced risk of hyperkalemia during treatment of heart failure with mineralocorticoid receptor antagonists by use of sacubitril\/valsartan compared with enalapril: a secondary analysis of the PARADIGM-HF trial","volume":"2","author":"Desai","year":"2017","journal-title":"JAMA Cardiol"},{"key":"B48","doi-asserted-by":"publisher","first-page":"12407","DOI":"10.1080\/21655979.2021.2005219","article-title":"N-terminal prohormone B-type natriuretic peptide variability acts as a predictor of poor prognosis in patients with cardiorenal syndrome type 2","volume":"12","author":"Ma","year":"2021","journal-title":"Bioengineered"},{"key":"B49","doi-asserted-by":"publisher","first-page":"e004446","DOI":"10.1161\/CIRCHEARTFAILURE.117.004446","article-title":"Independent prognostic value of Serum soluble ST2 measurements in patients with heart failure and a reduced ejection fraction in the PARADIGM-HF trial (prospective comparison of ARNI with ACEI to determine impact on global mortality and morbidity in heart failure)","volume":"11","author":"O'Meara","year":"2018","journal-title":"Circ Heart Fail"},{"key":"B50","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1016\/j.jacc.2018.11.042","article-title":"Effects of sacubitril\/valsartan on biomarkers of extracellular matrix regulation in patients with HFrEF","volume":"73","author":"Zile","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"B51","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1056\/NEJMoa1908655","article-title":"Angiotensin-Neprilysin inhibition in heart failure with preserved ejection fraction","volume":"381","author":"Solomon","year":"2019","journal-title":"N Engl J Med"},{"key":"B52","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1161\/CIRCULATIONAHA.119.044586","article-title":"Sacubitril\/valsartan across the Spectrum of ejection fraction in heart failure","volume":"141","author":"Solomon","year":"2020","journal-title":"Circulation"},{"key":"B53","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1161\/CIRCULATIONAHA.119.044491","article-title":"Effects of sacubitril-valsartan versus valsartan in women compared with men with heart failure and preserved ejection fraction: insights from PARAGON-HF","volume":"141","author":"McMurray","year":"2020","journal-title":"Circulation"},{"key":"B54","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1161\/circulationaha.120.047643","article-title":"Angiotensin-Neprilysin inhibition and renal outcomes in heart failure with preserved ejection fraction","volume":"142","author":"Causland FR","year":"2020","journal-title":"Circulation"},{"key":"B55","doi-asserted-by":"publisher","first-page":"e022069","DOI":"10.1161\/JAHA.121.022069","article-title":"Effects of sacubitril\/valsartan on Serum lipids in heart failure with preserved ejection fraction","volume":"10","author":"Selvaraj","year":"2021","journal-title":"J Am Heart Assoc"},{"key":"B56","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1016\/j.jacc.2020.05.072","article-title":"Effect of sacubitril\/valsartan on biomarkers of extracellular matrix regulation in patients with HFpEF","volume":"76","author":"Cunningham","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"B57","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1002\/ejhf.1498","article-title":"Initiation of sacubitril\/valsartan in haemodynamically stabilised heart failure patients in hospital or early after discharge: primary results of the randomised TRANSITION study","volume":"21","author":"Wachter","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"B58","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1002\/ejhf.1670","article-title":"Initiation of sacubitril\/valsartan shortly after hospitalisation for acutely decompensated heart failure in patients with newly diagnosed (de novo) heart failure: a subgroup analysis of the TRANSITION study","volume":"22","author":"Senni","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"B59","doi-asserted-by":"publisher","first-page":"1354","DOI":"10.1161\/circulationaha.118.037077","article-title":"Angiotensin receptor neprilysin inhibitor for functional mitral regurgitation","volume":"139","author":"Kang","year":"2019","journal-title":"Circulation"},{"key":"B60","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1056\/NEJMoa1812851","article-title":"Angiotensin-Neprilysin inhibition in acute decompensated heart failure","volume":"380","author":"Velazquez","year":"2019","journal-title":"N Engl J Med"},{"key":"B61","doi-asserted-by":"publisher","first-page":"3345","DOI":"10.1093\/eurheartj\/ehz240","article-title":"Cardiovascular biomarkers in patients with acute decompensated heart failure randomized to sacubitril-valsartan or enalapril in the PIONEER-HF trial","volume":"40","author":"Morrow","year":"2019","journal-title":"Eur Heart J"},{"key":"B62","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1001\/jamacardio.2019.4665","article-title":"Initiation of angiotensin-neprilysin inhibition after acute decompensated heart failure: secondary analysis of the open-label extension of the PIONEER-HF trial","volume":"5","author":"DeVore","year":"2020","journal-title":"JAMA Cardiol"},{"key":"B63","doi-asserted-by":"publisher","first-page":"e007891","DOI":"10.1161\/circheartfailure.120.007891","article-title":"Hemodynamic effects of sacubitril-valsartan versus enalapril in patients with heart failure in the EVALUATE-HF study: effect modification by left ventricular ejection fraction and sex","volume":"14","author":"Mitchell","year":"2021","journal-title":"Circ Heart Fail"},{"key":"B64","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1001\/jama.2019.12843","article-title":"Effect of sacubitril-valsartan vs enalapril on aortic stiffness in patients with heart failure and reduced ejection fraction: a randomized clinical trial","volume":"322","author":"Desai","year":"2019","journal-title":"Jama"},{"key":"B65","doi-asserted-by":"publisher","first-page":"e008410","DOI":"10.1161\/circheartfailure.120.008410","article-title":"Association between angiotensin receptor-neprilysin inhibition, cardiovascular biomarkers, and cardiac remodeling in heart failure with reduced ejection fraction","volume":"14","author":"Murphy","year":"2021","journal-title":"Circ Heart Fail"},{"key":"B66","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.jchf.2020.09.013","article-title":"Atrial natriuretic peptide and treatment with sacubitril\/valsartan in heart failure with reduced ejection fraction","volume":"9","author":"Murphy","year":"2021","journal-title":"JACC Heart Fail"},{"key":"B67","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.jchf.2020.09.012","article-title":"Improvement of health Status following initiation of sacubitril\/valsartan in heart failure and reduced ejection fraction","volume":"9","author":"Pi\u00f1a","year":"2021","journal-title":"JACC Heart Fail"},{"key":"B68","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.cardfail.2016.06.006","article-title":"Prognostic value of insulin-like growth factor-binding protein 7 in patients with heart failure and preserved ejection fraction","volume":"23","author":"Gandhi","year":"2017","journal-title":"J Card Fail"},{"key":"B69","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1093\/eurjhf\/hft052","article-title":"Dual angiotensin receptor and neprilysin inhibition as an alternative to angiotensin-converting enzyme inhibition in patients with chronic systolic heart failure: rationale for and design of the prospective comparison of ARNI with ACEI to determine impact on global mortality and morbidity in heart failure trial (PARADIGM-HF)","volume":"15","author":"McMurray","year":"2013","journal-title":"Eur J Heart Fail"},{"key":"B70","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1007\/s11936-013-0249-2","article-title":"Assessing the impact of heart failure therapeutics on quality of life and functional capacity","volume":"15","author":"Lewis","year":"2013","journal-title":"Curr Treat Options Cardiovasc Med"},{"key":"B71","doi-asserted-by":"publisher","first-page":"e003358","DOI":"10.1161\/CIRCHEARTFAILURE.116.003358","article-title":"Exploring new endpoints for patients with heart failure with preserved ejection fraction","volume":"9","author":"Butler","year":"2016","journal-title":"Circ Heart Fail"},{"key":"B72","doi-asserted-by":"publisher","first-page":"e004962","DOI":"10.1161\/CIRCHEARTFAILURE.118.004962","article-title":"Baseline characteristics of patients with heart failure and preserved ejection fraction in the PARAGON-HF trial","volume":"11","author":"Solomon","year":"2018","journal-title":"Circ Heart Fail"},{"key":"B73","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1002\/ejhf.1159","article-title":"The role of angiotensin receptor-neprilysin inhibitors in cardiovascular disease-existing evidence, knowledge gaps, and future directions","volume":"20","author":"Ambrosy","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"B74","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1002\/ehf2.12246","article-title":"Rationale and design of TRANSITION: a randomized trial of pre-discharge vs. Post-discharge initiation of sacubitril\/valsartan","volume":"5","author":"Pascual-Figal","year":"2018","journal-title":"ESC Heart Fail"},{"key":"B75","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1016\/j.jacc.2020.06.073","article-title":"Angiotensin receptor-neprilysin inhibition based on history of heart failure and use of renin-angiotensin system antagonists","volume":"76","author":"Ambrosy","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"B76","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1016\/j.jchf.2020.06.008","article-title":"Efficacy and safety of sacubitril\/valsartan by dose level achieved in the PIONEER-HF trial","volume":"8","author":"Berg","year":"2020","journal-title":"JACC Heart Fail"},{"key":"B77","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1016\/j.jchf.2020.06.019","article-title":"Angiotensin-Neprilysin inhibition in black Americans: data from the PIONEER-HF trial","volume":"8","author":"Berardi","year":"2020","journal-title":"JACC Heart Fail"},{"key":"B78","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1001\/jama.2019.12821","article-title":"Association of change in N-terminal pro-B-type natriuretic peptide following initiation of sacubitril-valsartan treatment with cardiac structure and function in patients with heart failure with reduced ejection fraction","volume":"322","author":"Januzzi JL","year":"2019","journal-title":"JAMA"},{"key":"B79","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.jchf.2020.09.014","article-title":"Reverse cardiac remodeling following initiation of sacubitril\/valsartan in patients with heart failure with and without diabetes","volume":"9","author":"Khan","year":"2021","journal-title":"JACC Heart Fail"},{"key":"B80","doi-asserted-by":"publisher","first-page":"e007829","DOI":"10.1161\/circheartfailure.120.007829","article-title":"Racial and ethnic differences in biomarkers, health Status, and cardiac remodeling in patients with heart failure with reduced ejection fraction treated with sacubitril\/valsartan","volume":"13","author":"Ibrahim","year":"2020","journal-title":"Circ Heart Fail"},{"key":"B81","doi-asserted-by":"publisher","first-page":"109","DOI":"10.17219\/acem\/143433","article-title":"Impact of sacubitril\/valsartan on systolic heart failure: right heart location and clustering analysis","volume":"31","author":"Bouali","year":"2022","journal-title":"Adv Clin Exp Med"},{"key":"B82","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.ijcard.2022.01.004","article-title":"Working group on heart failure of the Italian society of C. Benefit from sacubitril\/valsartan is associated with hemodynamic improvement in heart failure with reduced ejection fraction: an echocardiographic study","volume":"350","author":"Carluccio","year":"2022","journal-title":"Int J Cardiol"},{"key":"B83","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1001\/jamacardio.2021.4567","article-title":"Effect of treatment with sacubitril\/valsartan in patients with advanced heart failure and reduced ejection fraction: a randomized clinical trial","volume":"7","author":"Mann","year":"2022","journal-title":"JAMA Cardiol"},{"key":"B84","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1093\/ehjcvp\/pvaa125","article-title":"Different left ventricular remodelling patterns and clinical outcomes between non-ischaemic and ischaemic aetiologies in heart failure patients receiving sacubitril\/valsartan treatment","volume":"8","author":"Lee","year":"2022","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"B85","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1161\/hypertensionaha.113.02002","article-title":"Efficacy and safety of LCZ696, a first-in-class angiotensin receptor neprilysin inhibitor, in Asian patients with hypertension: a randomized, double-blind, placebo-controlled study","volume":"63","author":"Kario","year":"2014","journal-title":"Hypertension"},{"key":"B86","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1161\/hypertensionaha.116.08556","article-title":"Effects of sacubitril\/valsartan versus olmesartan on central hemodynamics in the elderly with systolic hypertension: the PARAMETER study","volume":"69","author":"Williams","year":"2017","journal-title":"Hypertension"},{"key":"B87","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1016\/s0140-6736(09)61966-8","article-title":"Blood-pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin: a randomised, double-blind, placebo-controlled, active comparator study","volume":"375","author":"Ruilope","year":"2010","journal-title":"Lancet"},{"key":"B88","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1111\/jch.14454","article-title":"Efficacy of angiotensin receptor neprilysin inhibitor in Asian patients with refractory hypertension","volume":"24","author":"Li","year":"2022","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"B89","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1111\/jch.14422","article-title":"Effects of sacubitril\/valsartan on resistant hypertension and myocardial work in hemodialysis patients","volume":"24","author":"Wang","year":"2022","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"B90","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1161\/hypertensionaha.116.08484","article-title":"Effects of sacubitril\/valsartan (LCZ696) on natriuresis, diuresis, blood pressures, and NT-proBNP in salt-sensitive hypertension","volume":"69","author":"Wang","year":"2017","journal-title":"Hypertension"},{"key":"B91","doi-asserted-by":"publisher","first-page":"3741","DOI":"10.1093\/eurheartj\/ehab499","article-title":"Sacubitril-valsartan as a treatment for apparent resistant hypertension in patients with heart failure and preserved ejection fraction","volume":"42","author":"Jackson","year":"2021","journal-title":"Eur Heart J"},{"key":"B92","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1007\/s00392-019-01440-y","article-title":"Sacubitril\/valsartan reduces ventricular arrhythmias in parallel with left ventricular reverse remodeling in heart failure with reduced ejection fraction","volume":"108","author":"Martens","year":"2019","journal-title":"Clin Res Cardiol"},{"key":"B93","doi-asserted-by":"publisher","first-page":"869","DOI":"10.3390\/jcm8060869","article-title":"Antiarrhythmic effect of sacubitril-valsartan: cause or consequence of clinical improvement?","volume":"8","author":"Valentim Gon\u00e7alves","year":"2019","journal-title":"J Clin Med"},{"key":"B94","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/j.hrthm.2017.11.012","article-title":"Effects of angiotensin-neprilysin inhibition compared to angiotensin inhibition on ventricular arrhythmias in reduced ejection fraction patients under continuous remote monitoring of implantable defibrillator devices","volume":"15","author":"de Diego","year":"2018","journal-title":"Heart Rhythm"},{"key":"B95","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1016\/j.cardfail.2020.03.007","article-title":"Sacubitril\/valsartan therapy ameliorates ventricular tachyarrhythmia inducibility in a rabbit myocardial infarction model","volume":"26","author":"Chang","year":"2020","journal-title":"J Card Fail"},{"key":"B96","doi-asserted-by":"publisher","first-page":"6032631","DOI":"10.1155\/2019\/6032631","article-title":"LCZ696 Therapy reduces ventricular tachyarrhythmia inducibility in a myocardial infarction-induced heart failure rat model","volume":"2019","author":"Chang","year":"2019","journal-title":"Cardiovasc Ther"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1007\/s10557-022-07315-1","article-title":"Sacubitril\/valsartan can reduce atrial fibrillation recurrence after catheter ablation in patients with persistent atrial fibrillation","author":"Wang","year":"2022","journal-title":"Cardiovasc Drugs Ther"},{"key":"B98","doi-asserted-by":"publisher","first-page":"e0263131","DOI":"10.1371\/journal.pone.0263131","article-title":"Role of sacubitril-valsartan in the prevention of atrial fibrillation occurrence in patients with heart failure: a systematic review and meta-analysis of randomized controlled trials","volume":"17","author":"Liu","year":"2022","journal-title":"PLoS One"},{"key":"B99","doi-asserted-by":"publisher","first-page":"734697","DOI":"10.3389\/fcvm.2021.734697","article-title":"Reduction of pulmonary hypertension after transition to sacubitril\/valsartan in patients with heart failure with preserved ejection fraction","volume":"8","author":"Burgdorf","year":"2021","journal-title":"Front Cardiovasc Med"},{"key":"B100","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1177\/1479164116653342","article-title":"Diabetes mellitus is associated with adverse structural and functional cardiac remodelling in chronic heart failure with reduced ejection fraction","volume":"13","author":"Walker","year":"2016","journal-title":"Diab Vasc Dis Res"},{"key":"B101","doi-asserted-by":"publisher","first-page":"002560","DOI":"10.1161\/circheartfailure.115.002560","article-title":"Risk related to Pre-diabetes Mellitus and diabetes Mellitus in heart failure with reduced ejection fraction: insights from prospective comparison of ARNI with ACEI to determine impact on global mortality and morbidity in heart failure trial","volume":"9","author":"Kristensen","year":"2016","journal-title":"Circ Heart Fail"},{"key":"B102","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1016\/s2213-8587(18)30100-1","article-title":"Effect of neprilysin inhibition on renal function in patients with type 2 diabetes and chronic heart failure who are receiving target doses of inhibitors of the renin-angiotensin system: a secondary analysis of the PARADIGM-HF trial","volume":"6","author":"Packer","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B103","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1002\/ejhf.2450","article-title":"Effects of sacubitril\/valsartan versus valsartan on renal function in patients with and without diabetes and heart failure with preserved ejection fraction: insights from PARAGON-HF","volume":"24","author":"Peikert","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"B104","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/j.jchf.2018.02.004","article-title":"Renal effects and associated outcomes during angiotensin-neprilysin inhibition in heart failure","volume":"6","author":"Damman","year":"2018","journal-title":"JACC Heart Fail"},{"key":"B105","doi-asserted-by":"publisher","first-page":"173444","DOI":"10.1016\/j.ejphar.2020.173444","article-title":"Effects of sacubitril\/valsartan in patients with heart failure and chronic kidney disease: a meta-analysis","volume":"884","author":"Kang","year":"2020","journal-title":"Eur J Pharmacol"},{"key":"B106","doi-asserted-by":"publisher","first-page":"173120","DOI":"10.1016\/j.ejphar.2020.173120","article-title":"Sacubitril\/valsartan attenuates atrial electrical and structural remodelling in a rabbit model of atrial fibrillation","volume":"881","author":"Li","year":"2020","journal-title":"Eur J Pharmacol"},{"key":"B107","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1007\/s12265-021-10137-5","article-title":"Sacubitril\/valsartan decreases atrial fibrillation susceptibility by inhibiting angiotensin II-induced atrial fibrosis through p-Smad2\/3, p-JNK, and p-p38 signaling pathways","volume":"15","author":"Li","year":"2021","journal-title":"J Cardiovasc Transl Res"},{"key":"B108","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1093\/cvr\/cvaa200","article-title":"Additive protective effects of sacubitril\/valsartan and bosentan on vascular remodelling in experimental pulmonary hypertension","volume":"117","author":"Chaumais","year":"2021","journal-title":"Cardiovasc Res"},{"key":"B109","doi-asserted-by":"publisher","first-page":"e005819","DOI":"10.1161\/circheartfailure.119.005819","article-title":"Treatment of pulmonary hypertension with angiotensin II receptor blocker and neprilysin inhibitor sacubitril\/valsartan","volume":"12","author":"Clements","year":"2019","journal-title":"Circ Heart Fail"},{"key":"B110","doi-asserted-by":"publisher","first-page":"e015708","DOI":"10.1161\/jaha.119.015708","article-title":"Angiotensin receptor-neprilysin inhibition attenuates right ventricular remodeling in pulmonary hypertension","volume":"9","author":"Sharifi Kia","year":"2020","journal-title":"J Am Heart Assoc"},{"key":"B111","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.ijcard.2019.06.065","article-title":"Effects of combined angiotensin II receptor antagonism and neprilysin inhibition in experimental pulmonary hypertension and right ventricular failure","volume":"293","author":"Andersen","year":"2019","journal-title":"Int J Cardiol"},{"key":"B112","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1042\/cs20160197","article-title":"Blood pressure-independent renoprotection in diabetic rats treated with AT1 receptor-neprilysin inhibition compared with AT1 receptor blockade alone","volume":"130","author":"Roksnoer","year":"2016","journal-title":"Clin Sci (Lond)"},{"key":"B113","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s12933-019-0847-8","article-title":"The combination of a neprilysin inhibitor (sacubitril) and angiotensin-II receptor blocker (valsartan) attenuates glomerular and tubular injury in the zucker obese rat","volume":"18","author":"Habibi","year":"2019","journal-title":"Cardiovasc Diabetol"},{"key":"B114","doi-asserted-by":"publisher","first-page":"1616","DOI":"10.2337\/db18-0062","article-title":"Vascular and neural complications in type 2 diabetic rats: improvement by sacubitril\/valsartan greater than valsartan alone","volume":"67","author":"Davidson","year":"2018","journal-title":"Diabetes"},{"key":"B115","doi-asserted-by":"publisher","first-page":"119692","DOI":"10.1016\/j.lfs.2021.119692","article-title":"Renal protective effects and mechanisms of the angiotensin receptor-neprilysin inhibitor LCZ696 in mice with cardiorenal syndrome","volume":"280","author":"Li","year":"2021","journal-title":"Life Sci"},{"key":"B116","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1016\/j.cardfail.2020.08.009","article-title":"Effects of angiotensin-neprilysin inhibition in canines with experimentally induced cardiorenal syndrome","volume":"26","author":"Sabbah","year":"2020","journal-title":"J Card Fail"},{"key":"B117","doi-asserted-by":"publisher","first-page":"e137","DOI":"10.1161\/cir.0000000000000509","article-title":"2017 ACC\/AHA\/HFSA focused update of the 2013 ACCF\/AHA guideline for the management of heart failure: a report of the American college of cardiology\/American heart association task force on clinical practice guidelines and the heart failure society of America","volume":"136","author":"Yancy","year":"2017","journal-title":"Circulation"},{"key":"B118","doi-asserted-by":"publisher","first-page":"e006696","DOI":"10.1161\/circheartfailure.119.006696","article-title":"Angiotensin receptor-neprilysin inhibitor therapy reverses pulmonary hypertension in End-stage heart failure patients awaiting transplantation","volume":"13","author":"Zern","year":"2020","journal-title":"Circ Heart Fail"},{"key":"B119","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/s2213-8587(17)30087-6","article-title":"Effect of sacubitril\/valsartan versus enalapril on glycaemic control in patients with heart failure and diabetes: a post-hoc analysis from the PARADIGM-HF trial","volume":"5","author":"Seferovic","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B120","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1161\/circulationaha.118.034818","article-title":"Effects of sacubitril\/valsartan versus irbesartan in patients with chronic kidney disease","volume":"138","author":"Haynes","year":"2018","journal-title":"Circulation"}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2023.1102521\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,28]],"date-time":"2023-03-28T05:00:44Z","timestamp":1679979644000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2023.1102521\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,28]]},"references-count":120,"alternative-id":["10.3389\/fcvm.2023.1102521"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2023.1102521","relation":{},"ISSN":["2297-055X"],"issn-type":[{"value":"2297-055X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,28]]},"article-number":"1102521"}}